Based on the key indicators related to Iteos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Iteos Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Iteos Therapeutics' Total Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 60 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 15.4 M in 2024. Key indicators impacting Iteos Therapeutics' financial strength include:
The financial analysis of Iteos Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Iteos Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(107.01 Million)
Iteos
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Net Borrowings
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Property Plant And Equipment Gross
Retained Earnings Total Equity
Capital Lease Obligations
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Cost Of Revenue
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Iteos Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Iteos Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Iteos Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.
Iteos Therapeutics Stock Summary
Iteos Therapeutics competes with Annexon, Monte Rosa, Design Therapeutics, Erasca, and Apellis Pharmaceuticals. Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Iteos Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Iteos Therapeutics's current stock value. Our valuation model uses many indicators to compare Iteos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iteos Therapeutics competition to find correlations between indicators driving Iteos Therapeutics's intrinsic value. More Info.
Iteos Therapeutics is rated fourth overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . At this time, Iteos Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Iteos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Iteos Therapeutics Systematic Risk
Iteos Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Iteos Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Iteos Therapeutics correlated with the market. If Beta is less than 0 Iteos Therapeutics generally moves in the opposite direction as compared to the market. If Iteos Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Iteos Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Iteos Therapeutics is generally in the same direction as the market. If Beta > 1 Iteos Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Iteos Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iteos Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Iteos Therapeutics growth as a starting point in their analysis.
Iteos Therapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Iteos Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Iteos Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Iteos Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Iteos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Iteos Therapeutics's daily price indicators and compare them against related drivers.
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.